Amoxicillin-clavulanate × Acute odontogenic infection clinical-success evidence sheet

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Efficacy comparison and presentation of stored materialWhat are the selected clinical-success question and existing verdict record?Required	The selected question is acute odontogenic infection clinical success. Subclaim grade C/note are retained; score, status and axes are unrecorded. Parent C50, caution and P/R1/I0/E+/B1 remain parent context. S01	This is a draft presentation of the stored summary. Some information exists, but Parent scores or axes are not inherited by the selected row, and no new verdict is created. Review of the table remains pending with the user.	Distinguishing subclaim grade C/note, parent C50/axes and absent score	Proposed later production record separating the subclaim question from parent clinical-cure context; no new investigation, calculation or trial is performed here.
2	Partly verified	Full text not readStored summary read	N02 · Efficacy comparison and presentation of stored materialWhat outcomes make up end-of-treatment clinical success?Required	The original endpoint is end-of-treatment clinical success, a composite of pain, swelling, fever and need for additional antibiotics. It is not changed into a laboratory surrogate. S01	This is a draft presentation of the stored summary. Some information exists, but Complete cure/improvement/failure classification, adjudication algorithms and component results are incomplete in the summary alone. Review of the table remains pending with the user.	Clinical composite definition of pain, swelling, fever and need for additional antibiotics	Proposed report material linking clinical success and each component separately; no new investigation, calculation or trial is performed here.
3	Partly verified	Full text not readStored summary read	N03 · Efficacy comparison and presentation of stored materialDo complete cure and improvement use the same criteria?Required	Original cure means complete resolution of baseline infection signs/symptoms with no additional antibiotics needed. Improvement means fever resolution, over 70% reduction in pain/swelling and no additional antibiotics needed. S01	This is a draft presentation of the stored summary. Some information exists, but Cure-only and improvement-only proportions and composite aggregation rules are unverified. Review of the table remains pending with the user.	Distinguishing complete resolution from fever resolution and over 70% reduction in pain/swelling	Proposed later material reporting separate effects for composite success and complete cure; no new investigation, calculation or trial is performed here.
4	Partly verified	Full text not readStored summary read	N04 · Efficacy comparison and presentation of stored materialWhich comparison do the 88.2% versus 89.7% success rates describe?Required	Original clinical success is 88.2% versus 89.7% for amoxicillin-clavulanate versus clindamycin. These values are not transferred to within-group change, complete cure alone or absolute effects versus placebo. S01	This is a draft presentation of the stored summary. Some information exists, but Actual successful-event counts/denominators, analysis populations and the exact two-sided interval are unverified. Review of the table remains pending with the user.	Distinguishing between-group end-of-treatment clinical success from within-group change/complete-cure rates	Proposed between-group report material aligning clinical-success definitions and analysis populations; no new investigation, calculation or trial is performed here.
5	Partly verified	Full text not readStored summary read	N05 · Efficacy comparison and presentation of stored materialWhat are the prespecified 10% noninferiority margin and 7.7% CI upper bound?Required	The stored summary reports a prespecified 10% noninferiority margin and a 95% CI upper bound of 7.7% within it. No complete CI, difference or new verdict is calculated. S01	This is a draft presentation of the stored summary. Some information exists, but Difference sign/reference group, CI lower bound, calculation model and prespecified-margin rationale are unverified. Review of the table remains pending with the user.	Distinguishing the original protocol-specified margin/CI upper bound from the complete interval	Proposed noninferiority report material specifying the contrast, sign and clinical margin rationale; no new investigation, calculation or trial is performed here.
6	Partly verified	Full text not readStored summary read	N06 · Efficacy comparison and presentation of stored materialDoes noninferiority imply equivalence or superiority?Required	The existing note concludes noninferiority. Two success rates and passage of the margin are not extended to no differences, equivalence, superiority or guaranteed individual treatment effects. S01	This is a draft presentation of the stored summary. Some information exists, but Prespecified equivalence/superiority hypotheses, tests and direct results are absent from the summary. Review of the table remains pending with the user.	Distinguishing the original noninferiority conclusion from identical/more effective conclusions	Proposed question-specific linking when comparative material with separate hypotheses is provided; no new investigation, calculation or trial is performed here.
7	Partly verified	Full text not readStored summary read	N07 · Efficacy comparison and presentation of stored materialIs the control a three-times-daily regimen of the same drug?Required	The original control is clindamycin 150 mg four times daily. It is not amoxicillin-clavulanate three times daily. S01	This is a draft presentation of the stored summary. Some information exists, but This trial has no direct results comparing dosing frequencies of the same ingredient. Review of the table remains pending with the user.	Distinguishing clindamycin active control from same-ingredient BID/TID comparison	Proposed material separately studying same-ingredient dosing frequency; no new investigation, calculation or trial is performed here.
8	Partly verified	Full text not readStored summary read	N08 · Efficacy comparison and presentation of stored materialWhat research conditions describe the original amoxicillin-clavulanate exposure?Required	The original intervention is 875/125 mg twice daily under 5~7-day acute-infection research conditions. This is not written as dosing, selection, administration or change guidance. S01	This is a draft presentation of the stored summary. Some information exists, but Actual exposure/adherence, duration selection, crossover/discontinuation and formulation details are unverified. Review of the table remains pending with the user.	Distinguishing 875/125 mg twice-daily short-term research exposure from use guidance	Proposed later report separating trial conditions from actual deviations; no new investigation, calculation or trial is performed here.
9	Partly verified	Full text not readStored summary read	N09 · Efficacy comparison and presentation of stored materialWhat are the actual population and infection scope?Required	The original trial included 472 people with acute odontogenic infection. Absent age, severity, fever/immune status, region or other conditions are not filled in, and results are not generalized to all dental infections. S01	This is a draft presentation of the stored summary. Some information exists, but Exact eligibility/exclusions, age, infection type/baseline symptoms, comorbidities and recruitment conditions are unverified. Review of the table remains pending with the user.	Acute odontogenic infection population, eligibility/baseline severity and recruitment scope	Proposed later material distinguishing the original population from other infections/vulnerable populations; no new investigation, calculation or trial is performed here.
10	Partly verified	Full text not readStored summary read	N10 · Efficacy comparison and presentation of stored materialWhat denominators do 472 randomized and 235/237 represent?Required	Original n is 472 randomized (235/237). Numbers and order are retained without calculating successful events, safety denominators or group dropout counts. S01	This is a draft presentation of the stored summary. Some information exists, but Explicit group labels for 235/237, actual assessed participants/successful events and analysis denominators are unverified. Review of the table remains pending with the user.	Distinguishing randomized counts/original group array from clinical-success analysis denominators	Proposed report material linking separate denominators to clinical-success and safety results; no new investigation, calculation or trial is performed here.
11	Partly verified	Full text not readStored summary read	N11 · Efficacy comparison and presentation of stored materialAre ITT, PP, missingness and noninferiority analyses distinguished?Required	The stored summary provides a noninferiority conclusion and randomized counts. It does not establish concordant ITT/PP results or absence of missingness. S01	This is a draft presentation of the stored summary. Some information exists, but ITT/PP definitions, exclusions/missingness, dropout, sensitivity and group analysis counts are unverified. Review of the table remains pending with the user.	Noninferiority analysis populations, missingness/discontinuation and sensitivity specifications	Proposed later material disclosing analysis-population-specific noninferiority results and missingness assumptions; no new investigation, calculation or trial is performed here.
12	Partly verified	Full text not readStored summary read	N12 · Efficacy comparison and presentation of stored materialWhat does observer blinding cover?Required	The original is a randomized observer-blind phase 4 noninferiority trial. It is not changed into verified patient/administrator double blinding or allocation concealment. S01	This is a draft presentation of the stored summary. Some information exists, but Sequence generation/concealment, assessor/patient awareness, maintenance of blinding and breaches are unverified. Review of the table remains pending with the user.	Distinguishing observer blinding from patient/administrator/analyst blinding	Proposed report linking the scope of blinding to composite clinical-success adjudication; no new investigation, calculation or trial is performed here.
13	Partly verified	Full text not readStored summary read	N13 · Efficacy comparison and presentation of stored materialHow were VAS, fever and rescue antibiotics assessed?Required	The existing verdict rationale describes a patient-centred endpoint combining pain/swelling VAS, fever and rescue antibiotics. Individual between-group benefits for components are not invented. S01	This is a draft presentation of the stored summary. Some information exists, but VAS scale/baseline, fever definition, measurement timing, assessors and rescue-antibiotic criteria are unverified. Review of the table remains pending with the user.	Symptom measurement, assessors, composite adjudication and rescue treatment	Proposed outcome report separating symptoms from need for additional treatment; no new investigation, calculation or trial is performed here.
14	Partly verified	Full text not readStored summary read	N14 · Efficacy comparison and presentation of stored materialAre the 5~7-day end of treatment and later recurrence the same window?Required	Original treatment/observation wording specifies 5~7 days and does not answer long-term recurrence or complications. It is not extended to long-term cure or recurrence prevention. S01	This is a draft presentation of the stored summary. Some information exists, but Exact visit windows, extension decisions, later recurrence/complication definitions and denominators are unverified. Review of the table remains pending with the user.	Acute end-of-treatment visits, duration variation and long-term follow-up	Proposed material assessing acute success and later recurrence/complications separately; no new investigation, calculation or trial is performed here.
15	Partly verified	Full text not readStored summary read	N15 · Efficacy comparison and presentation of stored materialHow do drainage, dental procedures and concurrent exposure relate to results?Required	The existing research explanation about difficulty giving placebo alone instead of drainage/antibiotics is historical design commentary. It is not changed into actual drainage or equivalent care for every participant. S01	This is a draft presentation of the stored summary. Some information exists, but Group differences in actual drainage/surgery, analgesics, concurrent care and treatment deviations/rescue are unverified. Review of the table remains pending with the user.	Original ethical-control explanation and actual shared/group-specific procedures	Proposed report distinguishing contributions of the antibiotic comparison and concurrent procedures; no new investigation, calculation or trial is performed here.
16	Partly verified	Full text not readStored summary read	N16 · Efficacy comparison and presentation of stored materialCan this comparison establish absolute efficacy versus placebo?Required	The existing counterargument says absolute efficacy versus placebo was not tested. Active-control success rates are not used to calculate improvement without treatment, absolute effects or individual need. S01	This is a draft presentation of the stored summary. Some information exists, but Direct results for placebo/no-treatment comparisons are absent. Review of the table remains pending with the user.	Distinguishing active-control noninferiority from effects versus placebo/no treatment	Proposed separate material for comparison questions distinguishing ethical/research conditions; no new investigation, calculation or trial is performed here.
17	Partly verified	Full text not readStored summary read	N17 · Efficacy comparison and presentation of stored materialWhat are the prespecified clinical-success endpoint/timepoint and multiplicity?Required	The original reports a prespecified noninferiority margin; this does not mean every symptom, visit or safety outcome was a prespecified primary endpoint. S01	This is a draft presentation of the stored summary. Some information exists, but Registration/protocol/SAP primary/secondary endpoints, visits, multiplicity and change histories remain unread. Review of the table remains pending with the user.	Protocol-specified noninferiority specifications and hierarchy of other outcomes	Proposed material making prespecified plans and reported endpoints/timepoints comparable; no new investigation, calculation or trial is performed here.
18	Partly verified	Full text not readStored summary read	N18 · Efficacy comparison and presentation of stored materialHow are GSK funding, editorial support and employee authors distinguished?Required	Original funding information specifies GSK funding and DiagnoSearch editorial support, with stock/equity disclosures by four GSK employee authors. This is not current external COI reading or independence certification. S01	This is a draft presentation of the stored summary. Some information exists, but Funding/editorial-support details, product supply, design/analysis/manuscript contributions and complete COI remain unread. Review of the table remains pending with the user.	Corporate funding, DiagnoSearch editorial support and employee stock/equity COI	Proposed report disclosing support separately from research/manuscript control; no new investigation, calculation or trial is performed here.
19	Partly verified	Full text not readStored summary read	N19 · Efficacy comparison and presentation of stored materialHow are manufacturer-sponsored trials and independent replication recorded?Required	Tancawan2015 AUG117044 and PMID26300919 link to the same stored report. Subclaim/parent, composite/component and safety results are not added as new independent trials or participant totals. S01	This is a draft presentation of the stored summary. Some information exists, but New unique trial/participant or independent-replication counts are not established and remain null. Review of the table remains pending with the user.	One AUG117044 trial with shared bibliographic/subclaim/parent results	Proposed linking that distinguishes trial-family and outcome relationships when new material is provided; no new investigation, calculation or trial is performed here.
20	Partly verified	Full text not readStored summary read	N20 · Efficacy comparison and presentation of stored materialDoes NCT02141217 mean registration was read here?Required	The original identifier NCT02141217 is retained exactly. Its presence is not upgraded to registration-content verification, confirmed prespecified endpoints/analyses or successful access here. S01	This is a draft presentation of the stored summary. Some information exists, but Original registration/changes, protocol and SAP remain unread, with no access attempted. Review of the table remains pending with the user.	Distinguishing a literal registration number from actual reading of registration/changes/plans	Proposed material providing report-plan links and change histories; no new investigation, calculation or trial is performed here.
21	Partly verified	Full text not readStored summary read	N21 · Harm-information gaps supplementing the efficacy tableWhat safety outcomes do diarrhea, elevated liver enzymes and headache represent?Supplementary	The existing safety explanation reports diarrhea, elevated liver enzymes, headache and other events. Parent caution is an original value; no new event counts/rates, between-group harm differences or causal conclusions are created. S01	This is a draft presentation of the stored summary. Some information exists, but Group event counts/denominators, collection methods, severity, ascertainment/periods and CIs are unverified. Review of the table remains pending with the user.	Originally reported adverse events and safety-event definitions/denominators	Proposed safety report distinguishing symptoms, laboratory abnormalities and discontinuation; no new investigation, calculation or trial is performed here.
22	Partly verified	Full text not readStored summary read	N22 · Harm-information gaps supplementing the efficacy tableWhat is known about allergy/liver risk, vulnerable populations and long-term outcomes?Supplementary	Original penicillin-allergy and liver-risk safety wording is preserved as historical text. It is not changed into drug-selection/change or suitability guidance, or long-term/vulnerable-population safety certification. S01	This is a draft presentation of the stored summary. Some information exists, but Risk-population inclusion/exclusion, occurrence/causality, long-term/delayed outcomes and missingness are unverified. Review of the table remains pending with the user.	Original safety history and directly studied risk/follow-up scope	Proposed safety material distinguishing the original population from vulnerable populations; no new investigation, calculation or trial is performed here.
23	Partly verified	Full text not readStored summary read	N23 · Harm-information gaps supplementing the efficacy tableCan adherence benefits be inferred from safety or convenience?Supplementary	The existing counterpoint says dosing convenience is not direct frequency-comparison evidence. Frequency is not used to calculate or recommend adherence rates, side-effect improvements or actual dosing behaviour. S01	This is a draft presentation of the stored summary. Some information exists, but Adherence, convenience scales and same-drug frequency-comparison results are unverified. Review of the table remains pending with the user.	BID convenience wording and direct adherence/harm/frequency comparisons	Proposed material reporting clinical success, adherence and harms separately; no new investigation, calculation or trial is performed here.
24	Partly verified	Full text not readStored summary read	N24 · Efficacy comparison and presentation of stored materialWhat is the historical defect assessment for short follow-up, sample size and control?Required	The existing research explanation says the under-200 criterion did not apply and that acute 5~7-day follow-up/active control were not counted as avoidable defects. This is not inherited as current reassessment, QA or certification of defect-free design. S01	This is a draft presentation of the stored summary. Some information exists, but No original-text comparison or new defect/grade application is performed here. Review of the table remains pending with the user.	Original historical assessment of 472 people, 5~7 days and active control	Proposed later record separating the original design assessment from new evidence-update events; no new investigation, calculation or trial is performed here.
25	Partly verified	Full text not readStored summary read	N25 · Efficacy comparison and presentation of stored materialCan Korean prescribing/practicality wording be used as current recommendations?Required	Original Korean dental-prescribing/practicality wording is retained in the complete existing review summary. No current policy, approval, product-selection, frequency or treatment recommendations are added. S01	This is a draft presentation of the stored summary. Some information exists, but Current operational/recommendation updates or direct evidence for other formulations/populations/durations are outside this scope. Review of the table remains pending with the user.	Distinguishing original advertising-interpretation history from current policy/product/dosing verification	Proposed later material record distinguishing historical wording from current material; no new investigation, calculation or trial is performed here.
26	Partly verified	Full text not readStored summary read	N26 · Efficacy comparison and presentation of stored materialAt what level were the stored summary, external papers and source links read?Required	The complete stored summary was read for production and marked as summary reading. Only the original PubMed URL is retained; paper/abstract/full text, registration, plans and COI remain unread. S01	This is a draft presentation of the stored summary. Some information exists, but External access, link/click tests and original-source identity/content comparisons were not performed. Review of the table remains pending with the user.	Complete original stored summary; PMID26300919, registration/plans/COI remain unread	Proposed later record separating actual acquisition/reading scope for each material; no new investigation, calculation or trial is performed here.
27	Partly verified	Full text not readStored summary read	N27 · Efficacy comparison and presentation of stored materialHow are Korean/English, dates, corrections, empty values and cross-check history retained?Required	Complete Korean/English articles, subclaim grade C, parent C50/caution, unrecorded precision/false flags, empty correction/deliberation values and reference date are preserved in their original form. Original cross-check wording is historical and does not mean completed review here. S01	This is a draft presentation of the stored summary. Some information exists, but No translation/content review, correction, new verdict or external update is performed here. Review of the table remains pending with the user.	Subclaim C/note, parent C50/caution, 2026-08-26 and original false/null/empty values	Proposed later production record separating original preservation from correction/update events; no new investigation, calculation or trial is performed here.
28	Partly verified	Full text not readStored summary read	N28 · Efficacy comparison and presentation of stored materialAre condition freezing/application, case storage and user review separate events?Required	Condition preservation/application, case production and completed review are separate records. Review of the existing content is incomplete and is distinguished from production. S01	This is a draft presentation of the stored summary. Some information exists, but User review is incomplete; no post-storage rereading, review, checks/tests or link/screen verification is performed. Review of the table remains pending with the user.	Prior condition storage, freezing, separate application/case and incomplete-review flags	Proposed later work recording production separately from user correction/review events; no new investigation, calculation or trial is performed here.

No items match your search or filter.

28 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Acute odontogenic infection; 472 randomized (235/237). Actual eligibility, efficacy/safety analysis denominators and group labels are unverified
Ingredient, formulation and route: Historical trial exposure to amoxicillin-clavulanate 875/125 mg twice daily for 5~7 days; not dosing or treatment-selection guidance
Dose: Not recorded
Comparator: Active control: clindamycin 150 mg four times daily; not the same drug BID versus TID or a placebo comparison
Measured outcome: End-of-treatment clinical success: composite of pain, swelling, fever and need for additional antibiotics; distinguished from cure/improvement and individual outcomes
Duration: Original 5~7-day acute end-of-treatment assessment; later recurrence/long-term complications are unverified
Questions outside this scope: Repurposing composite clinical success as complete cure alone, individual symptoms, or prevention of long-term recurrence/complications; Extending passage of the 10% noninferiority margin/7.7% CI upper bound to equivalence, superiority or absence of all differences; Calculating new differences, event counts/denominators, complete CIs, effects or rates from 88.2%/89.7% and 472/235/237; Filling in explicit group labels, efficacy/safety analysis denominators or no dropouts from the original 235/237; Changing the clindamycin active control to the same drug three times daily, placebo or no treatment; Inheriting observer-blind wording as verified patient/administrator double blinding or allocation concealment; Treating the original drainage/placebo ethics explanation as actual drainage or equivalent concurrent care for every participant; Adding shared report, parent/subclaim, composite/component, safety or timepoint results as independent trials/participant totals; Inheriting GSK/editorial support and employee stock/equity wording as current COI reading or independent certification; Converting original adverse-event, caution and risk-population wording into safety event counts/rates, long-term/vulnerable-population certification or drug-selection/dosing/change guidance; Upgrading an NCT number, bibliographic URL or historical cross-check/design-defect assessment to current registration/full-text reading or QA; Filling absent subclaim score/status/axes with parent C50/axes, or creating new grades/reassessment; New clinical searches/APIs, calculations, hypothetical numbers, effects/CIs, independent certification or treatment/dosing/suitability recommendations

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Tancawan AL et al. 2015 AUG117044

PubMed

Material type: Randomized observer-blind phase 4 noninferiority trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: The original subclaim C/note describes noninferiority with 88.2% versus 89.7%. The end-of-treatment composite covers pain/swelling/fever/need for additional antibiotics, distinguishing cure from improvement with over 70% reduction. Original 10% margin/7.7% CI upper bound are retained without new differences/complete CIs or denominator calculations. GSK funding, DiagnoSearch editorial support, four employee authors with stock/equity and diarrhea/elevated liver enzymes/headache remain historical wording. Original parent C50/caution and cross-check/defect assessment are not inherited as new verdicts, QA or safety/independence certification.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 Tancawan2015 AUG117044/PMID26300919/NCT02141217 is a stored report of the same randomized observer-blind phase 4 noninferiority trial with 472 people (235/237). Parent clinical cure, subclaim clinical success and component/safety results link to the same report/population and are not added as new independent trials/participants. Unique clinical totals remain null; entry counts are not independent totals.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored evidence and bibliography summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
Paper, abstract and full text	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration and change history	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Prespecified study protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
SAP and prespecified analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Original funding, product support, employee-author and conflict-of-interest disclosures	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 Tancawan2015 AUG117044/PMID26300919/NCT02141217 is a stored report of the same randomized observer-blind phase 4 noninferiority trial with 472 people (235/237). Parent clinical cure, subclaim clinical success and component/safety results link to the same report/population and are not added as new independent trials/participants. Unique clinical totals remain null; entry counts are not independent totals.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · What are the selected clinical-success question and existing verdict record?

Required materials and conditions: Distinguishing subclaim grade C/note, parent C50/axes and absent score
Conditions for verification: Relevant original material and analysis scope for Distinguishing subclaim grade C/note, parent C50/axes and absent score must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing subclaim grade C/note, parent C50/axes and absent score to connect material needed for the selected question with current material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N02 · What outcomes make up end-of-treatment clinical success?

Required materials and conditions: Clinical composite definition of pain, swelling, fever and need for additional antibiotics
Conditions for verification: Relevant original material and analysis scope for Clinical composite definition of pain, swelling, fever and need for additional antibiotics must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Clinical composite definition of pain, swelling, fever and need for additional antibiotics to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3; Question-specific outcome adaptation is Chamgap design; M08 Table 8.2.a and M03 §3.2.4; Chamgap application; M03 §3.2.4; Chamgap interpretation boundary

N03 · Do complete cure and improvement use the same criteria?

Required materials and conditions: Distinguishing complete resolution from fever resolution and over 70% reduction in pain/swelling
Conditions for verification: Relevant original material and analysis scope for Distinguishing complete resolution from fever resolution and over 70% reduction in pain/swelling must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing complete resolution from fever resolution and over 70% reduction in pain/swelling to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M08 §8.2.2, M15 §15.3.1; internal application

N04 · Which comparison do the 88.2% versus 89.7% success rates describe?

Required materials and conditions: Distinguishing between-group end-of-treatment clinical success from within-group change/complete-cure rates
Conditions for verification: Relevant original material and analysis scope for Distinguishing between-group end-of-treatment clinical success from within-group change/complete-cure rates must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing between-group end-of-treatment clinical success from within-group change/complete-cure rates to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application

N05 · What are the prespecified 10% noninferiority margin and 7.7% CI upper bound?

Required materials and conditions: Distinguishing the original protocol-specified margin/CI upper bound from the complete interval
Conditions for verification: Relevant original material and analysis scope for Distinguishing the original protocol-specified margin/CI upper bound from the complete interval must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing the original protocol-specified margin/CI upper bound from the complete interval to connect material needed for the selected question with current material.
Referenced methods: M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application

N06 · Does noninferiority imply equivalence or superiority?

Required materials and conditions: Distinguishing the original noninferiority conclusion from identical/more effective conclusions
Conditions for verification: Relevant original material and analysis scope for Distinguishing the original noninferiority conclusion from identical/more effective conclusions must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing the original noninferiority conclusion from identical/more effective conclusions to connect material needed for the selected question with current material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application

N07 · Is the control a three-times-daily regimen of the same drug?

Required materials and conditions: Distinguishing clindamycin active control from same-ingredient BID/TID comparison
Conditions for verification: Relevant original material and analysis scope for Distinguishing clindamycin active control from same-ingredient BID/TID comparison must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing clindamycin active control from same-ingredient BID/TID comparison to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

N08 · What research conditions describe the original amoxicillin-clavulanate exposure?

Required materials and conditions: Distinguishing 875/125 mg twice-daily short-term research exposure from use guidance
Conditions for verification: Relevant original material and analysis scope for Distinguishing 875/125 mg twice-daily short-term research exposure from use guidance must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing 875/125 mg twice-daily short-term research exposure from use guidance to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

N09 · What are the actual population and infection scope?

Required materials and conditions: Acute odontogenic infection population, eligibility/baseline severity and recruitment scope
Conditions for verification: Relevant original material and analysis scope for Acute odontogenic infection population, eligibility/baseline severity and recruitment scope must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Acute odontogenic infection population, eligibility/baseline severity and recruitment scope to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.1; Detailed population conditions are Chamgap design; M03 §3.2.1–3.2.4; Dose, duration and effect-modifier details are Chamgap design

N10 · What denominators do 472 randomized and 235/237 represent?

Required materials and conditions: Distinguishing randomized counts/original group array from clinical-success analysis denominators
Conditions for verification: Relevant original material and analysis scope for Distinguishing randomized counts/original group array from clinical-success analysis denominators must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing randomized counts/original group array from clinical-success analysis denominators to connect material needed for the selected question with current material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N11 · Are ITT, PP, missingness and noninferiority analyses distinguished?

Required materials and conditions: Noninferiority analysis populations, missingness/discontinuation and sensitivity specifications
Conditions for verification: Relevant original material and analysis scope for Noninferiority analysis populations, missingness/discontinuation and sensitivity specifications must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Noninferiority analysis populations, missingness/discontinuation and sensitivity specifications to connect material needed for the selected question with current material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application

N12 · What does observer blinding cover?

Required materials and conditions: Distinguishing observer blinding from patient/administrator/analyst blinding
Conditions for verification: Relevant original material and analysis scope for Distinguishing observer blinding from patient/administrator/analyst blinding must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing observer blinding from patient/administrator/analyst blinding to connect material needed for the selected question with current material.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

N13 · How were VAS, fever and rescue antibiotics assessed?

Required materials and conditions: Symptom measurement, assessors, composite adjudication and rescue treatment
Conditions for verification: Relevant original material and analysis scope for Symptom measurement, assessors, composite adjudication and rescue treatment must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Symptom measurement, assessors, composite adjudication and rescue treatment to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3; Question-specific outcome adaptation is Chamgap design; M08 Table 8.2.a and M03 §3.2.4; Chamgap application; M03 §3.2.4; Chamgap interpretation boundary

N14 · Are the 5~7-day end of treatment and later recurrence the same window?

Required materials and conditions: Acute end-of-treatment visits, duration variation and long-term follow-up
Conditions for verification: Relevant original material and analysis scope for Acute end-of-treatment visits, duration variation and long-term follow-up must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Acute end-of-treatment visits, duration variation and long-term follow-up to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

N15 · How do drainage, dental procedures and concurrent exposure relate to results?

Required materials and conditions: Original ethical-control explanation and actual shared/group-specific procedures
Conditions for verification: Relevant original material and analysis scope for Original ethical-control explanation and actual shared/group-specific procedures must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Original ethical-control explanation and actual shared/group-specific procedures to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

N16 · Can this comparison establish absolute efficacy versus placebo?

Required materials and conditions: Distinguishing active-control noninferiority from effects versus placebo/no treatment
Conditions for verification: Relevant original material and analysis scope for Distinguishing active-control noninferiority from effects versus placebo/no treatment must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing active-control noninferiority from effects versus placebo/no treatment to connect material needed for the selected question with current material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

N17 · What are the prespecified clinical-success endpoint/timepoint and multiplicity?

Required materials and conditions: Protocol-specified noninferiority specifications and hierarchy of other outcomes
Conditions for verification: Relevant original material and analysis scope for Protocol-specified noninferiority specifications and hierarchy of other outcomes must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Protocol-specified noninferiority specifications and hierarchy of other outcomes to connect material needed for the selected question with current material.
Referenced methods: Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design; M08 Table 8.2.a and M04 §4.6.3; Chamgap application

N18 · How are GSK funding, editorial support and employee authors distinguished?

Required materials and conditions: Corporate funding, DiagnoSearch editorial support and employee stock/equity COI
Conditions for verification: Relevant original material and analysis scope for Corporate funding, DiagnoSearch editorial support and employee stock/equity COI must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Corporate funding, DiagnoSearch editorial support and employee stock/equity COI to connect material needed for the selected question with current material.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

N19 · How are manufacturer-sponsored trials and independent replication recorded?

Required materials and conditions: One AUG117044 trial with shared bibliographic/subclaim/parent results
Conditions for verification: Relevant original material and analysis scope for One AUG117044 trial with shared bibliographic/subclaim/parent results must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes One AUG117044 trial with shared bibliographic/subclaim/parent results to connect material needed for the selected question with current material.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N20 · Does NCT02141217 mean registration was read here?

Required materials and conditions: Distinguishing a literal registration number from actual reading of registration/changes/plans
Conditions for verification: Relevant original material and analysis scope for Distinguishing a literal registration number from actual reading of registration/changes/plans must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing a literal registration number from actual reading of registration/changes/plans to connect material needed for the selected question with current material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

N21 · What safety outcomes do diarrhea, elevated liver enzymes and headache represent?

Required materials and conditions: Originally reported adverse events and safety-event definitions/denominators
Conditions for verification: Relevant original material and analysis scope for Originally reported adverse events and safety-event definitions/denominators must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Supplementary
Application exceptions: This addresses harm-evidence gaps for the selected acute odontogenic infection clinical-success question. Original adverse-event/caution wording is not extended to overall safety or causal harm/rates, and no antibiotic-selection, dosing, administration/change or suitability guidance is created.
Why this condition is needed: This production item distinguishes Originally reported adverse events and safety-event definitions/denominators to connect material needed for the selected question with current material.
Referenced methods: M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Detailed distinctions are Chamgap design; M19 §19.1.2–19.2.4; Chamgap application; Chamgap interpretation boundary. M19 principles are referenced; no official causality tool was run

N22 · What is known about allergy/liver risk, vulnerable populations and long-term outcomes?

Required materials and conditions: Original safety history and directly studied risk/follow-up scope
Conditions for verification: Relevant original material and analysis scope for Original safety history and directly studied risk/follow-up scope must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Supplementary
Application exceptions: This addresses harm-evidence gaps for the selected acute odontogenic infection clinical-success question. Original adverse-event/caution wording is not extended to overall safety or causal harm/rates, and no antibiotic-selection, dosing, administration/change or suitability guidance is created.
Why this condition is needed: This production item distinguishes Original safety history and directly studied risk/follow-up scope to connect material needed for the selected question with current material.
Referenced methods: M19 §19.1.2–19.2.4; internal application; M19 §19.2 design-specific harm questions; temporal-relationship details are internally designed; M19 §19.2.2–19.2.4 design considerations; detailed confounding records are internally designed; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application; M19 §19.1.2–19.2.4; internal application; Chamgap interpretation limits, informed by M19 principles without running an official causality tool

N23 · Can adherence benefits be inferred from safety or convenience?

Required materials and conditions: BID convenience wording and direct adherence/harm/frequency comparisons
Conditions for verification: Relevant original material and analysis scope for BID convenience wording and direct adherence/harm/frequency comparisons must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Supplementary
Application exceptions: This addresses harm-evidence gaps for the selected acute odontogenic infection clinical-success question. Original adverse-event/caution wording is not extended to overall safety or causal harm/rates, and no antibiotic-selection, dosing, administration/change or suitability guidance is created.
Why this condition is needed: This production item distinguishes BID convenience wording and direct adherence/harm/frequency comparisons to connect material needed for the selected question with current material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M19 §19.1.2–19.2.4; internal application

N24 · What is the historical defect assessment for short follow-up, sample size and control?

Required materials and conditions: Original historical assessment of 472 people, 5~7 days and active control
Conditions for verification: Relevant original material and analysis scope for Original historical assessment of 472 people, 5~7 days and active control must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Original historical assessment of 472 people, 5~7 days and active control to connect material needed for the selected question with current material.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

N25 · Can Korean prescribing/practicality wording be used as current recommendations?

Required materials and conditions: Distinguishing original advertising-interpretation history from current policy/product/dosing verification
Conditions for verification: Relevant original material and analysis scope for Distinguishing original advertising-interpretation history from current policy/product/dosing verification must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Distinguishing original advertising-interpretation history from current policy/product/dosing verification to connect material needed for the selected question with current material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M03 §3.2.1; detailed population conditions are internally designed; M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N26 · At what level were the stored summary, external papers and source links read?

Required materials and conditions: Complete original stored summary; PMID26300919, registration/plans/COI remain unread
Conditions for verification: Relevant original material and analysis scope for Complete original stored summary; PMID26300919, registration/plans/COI remain unread must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Complete original stored summary; PMID26300919, registration/plans/COI remain unread to connect material needed for the selected question with current material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N27 · How are Korean/English, dates, corrections, empty values and cross-check history retained?

Required materials and conditions: Subclaim C/note, parent C50/caution, 2026-08-26 and original false/null/empty values
Conditions for verification: Relevant original material and analysis scope for Subclaim C/note, parent C50/caution, 2026-08-26 and original false/null/empty values must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Subclaim C/note, parent C50/caution, 2026-08-26 and original false/null/empty values to connect material needed for the selected question with current material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N28 · Are condition freezing/application, case storage and user review separate events?

Required materials and conditions: Prior condition storage, freezing, separate application/case and incomplete-review flags
Conditions for verification: Relevant original material and analysis scope for Prior condition storage, freezing, separate application/case and incomplete-review flags must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production item distinguishes Prior condition storage, freezing, separate application/case and incomplete-review flags to connect material needed for the selected question with current material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: A state used when required evidence is confirmed after user review. This production does not declare that review complete.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: User review pending.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-10 · Public page/material version 1.0

Public reader pages and material were prepared from the existing 28 items. No new clinical searches, verification-state changes or scoring were performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · What are the selected clinical-success question and existing verdict record?

Current findings: The selected question is acute odontogenic infection clinical success. Subclaim grade C/note are retained; score, status and axes are unrecorded. Parent C50, caution and P/R1/I0/E+/B1 remain parent context.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Parent scores or axes are not inherited by the selected row, and no new verdict is created. Review of the table remains pending with the user.
Reason for missing information: Parent scores or axes are not inherited by the selected row, and no new verdict is created.
Required materials and conditions: Distinguishing subclaim grade C/note, parent C50/axes and absent score
Materials to obtain first: Original selected-subclaim/parent-verdict records or user-corrected copies
Further research: Proposed later production record separating the subclaim question from parent clinical-cure context; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing subclaim grade C/note, parent C50/axes and absent score must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing subclaim grade C/note, parent C50/axes and absent score to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01

N02 · What outcomes make up end-of-treatment clinical success?

Current findings: The original endpoint is end-of-treatment clinical success, a composite of pain, swelling, fever and need for additional antibiotics. It is not changed into a laboratory surrogate.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Complete cure/improvement/failure classification, adjudication algorithms and component results are incomplete in the summary alone. Review of the table remains pending with the user.
Reason for missing information: Complete cure/improvement/failure classification, adjudication algorithms and component results are incomplete in the summary alone.
Required materials and conditions: Clinical composite definition of pain, swelling, fever and need for additional antibiotics
Materials to obtain first: Clinical-success adjudication tables, visit-specific classifications and complete original definitions
Further research: Proposed report material linking clinical success and each component separately; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Clinical composite definition of pain, swelling, fever and need for additional antibiotics must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Clinical composite definition of pain, swelling, fever and need for additional antibiotics to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3; Question-specific outcome adaptation is Chamgap design; M08 Table 8.2.a and M03 §3.2.4; Chamgap application; M03 §3.2.4; Chamgap interpretation boundary

Related sources S01

N03 · Do complete cure and improvement use the same criteria?

Current findings: Original cure means complete resolution of baseline infection signs/symptoms with no additional antibiotics needed. Improvement means fever resolution, over 70% reduction in pain/swelling and no additional antibiotics needed.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Cure-only and improvement-only proportions and composite aggregation rules are unverified. Review of the table remains pending with the user.
Reason for missing information: Cure-only and improvement-only proportions and composite aggregation rules are unverified.
Required materials and conditions: Distinguishing complete resolution from fever resolution and over 70% reduction in pain/swelling
Materials to obtain first: Cure/improvement/failure tables, VAS criteria and denominators
Further research: Proposed later material reporting separate effects for composite success and complete cure; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing complete resolution from fever resolution and over 70% reduction in pain/swelling must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing complete resolution from fever resolution and over 70% reduction in pain/swelling to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M08 §8.2.2, M15 §15.3.1; internal application

Related sources S01

N04 · Which comparison do the 88.2% versus 89.7% success rates describe?

Current findings: Original clinical success is 88.2% versus 89.7% for amoxicillin-clavulanate versus clindamycin. These values are not transferred to within-group change, complete cure alone or absolute effects versus placebo.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Actual successful-event counts/denominators, analysis populations and the exact two-sided interval are unverified. Review of the table remains pending with the user.
Reason for missing information: Actual successful-event counts/denominators, analysis populations and the exact two-sided interval are unverified.
Required materials and conditions: Distinguishing between-group end-of-treatment clinical success from within-group change/complete-cure rates
Materials to obtain first: Group-specific events/denominators, analysis populations and original outcome tables
Further research: Proposed between-group report material aligning clinical-success definitions and analysis populations; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing between-group end-of-treatment clinical success from within-group change/complete-cure rates must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing between-group end-of-treatment clinical success from within-group change/complete-cure rates to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application

Related sources S01

N05 · What are the prespecified 10% noninferiority margin and 7.7% CI upper bound?

Current findings: The stored summary reports a prespecified 10% noninferiority margin and a 95% CI upper bound of 7.7% within it. No complete CI, difference or new verdict is calculated.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Difference sign/reference group, CI lower bound, calculation model and prespecified-margin rationale are unverified. Review of the table remains pending with the user.
Reason for missing information: Difference sign/reference group, CI lower bound, calculation model and prespecified-margin rationale are unverified.
Required materials and conditions: Distinguishing the original protocol-specified margin/CI upper bound from the complete interval
Materials to obtain first: Protocol noninferiority specifications, complete original CI and analysis model
Further research: Proposed noninferiority report material specifying the contrast, sign and clinical margin rationale; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing the original protocol-specified margin/CI upper bound from the complete interval must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing the original protocol-specified margin/CI upper bound from the complete interval to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01

N06 · Does noninferiority imply equivalence or superiority?

Current findings: The existing note concludes noninferiority. Two success rates and passage of the margin are not extended to no differences, equivalence, superiority or guaranteed individual treatment effects.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Prespecified equivalence/superiority hypotheses, tests and direct results are absent from the summary. Review of the table remains pending with the user.
Reason for missing information: Prespecified equivalence/superiority hypotheses, tests and direct results are absent from the summary.
Required materials and conditions: Distinguishing the original noninferiority conclusion from identical/more effective conclusions
Materials to obtain first: Original plans specifying trial hypotheses, margins and analysis direction
Further research: Proposed question-specific linking when comparative material with separate hypotheses is provided; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing the original noninferiority conclusion from identical/more effective conclusions must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing the original noninferiority conclusion from identical/more effective conclusions to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M15 §15.3.1–15.3.3; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01

N07 · Is the control a three-times-daily regimen of the same drug?

Current findings: The original control is clindamycin 150 mg four times daily. It is not amoxicillin-clavulanate three times daily.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but This trial has no direct results comparing dosing frequencies of the same ingredient. Review of the table remains pending with the user.
Reason for missing information: This trial has no direct results comparing dosing frequencies of the same ingredient.
Required materials and conditions: Distinguishing clindamycin active control from same-ingredient BID/TID comparison
Materials to obtain first: Active-control specifications, formulation/dose/duration and actual administration records
Further research: Proposed material separately studying same-ingredient dosing frequency; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing clindamycin active control from same-ingredient BID/TID comparison must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing clindamycin active control from same-ingredient BID/TID comparison to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

Related sources S01

N08 · What research conditions describe the original amoxicillin-clavulanate exposure?

Current findings: The original intervention is 875/125 mg twice daily under 5~7-day acute-infection research conditions. This is not written as dosing, selection, administration or change guidance.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Actual exposure/adherence, duration selection, crossover/discontinuation and formulation details are unverified. Review of the table remains pending with the user.
Reason for missing information: Actual exposure/adherence, duration selection, crossover/discontinuation and formulation details are unverified.
Required materials and conditions: Distinguishing 875/125 mg twice-daily short-term research exposure from use guidance
Materials to obtain first: Group-specific actual exposure, adherence, change and discontinuation records
Further research: Proposed later report separating trial conditions from actual deviations; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing 875/125 mg twice-daily short-term research exposure from use guidance must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing 875/125 mg twice-daily short-term research exposure from use guidance to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

Related sources S01

N09 · What are the actual population and infection scope?

Current findings: The original trial included 472 people with acute odontogenic infection. Absent age, severity, fever/immune status, region or other conditions are not filled in, and results are not generalized to all dental infections.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Exact eligibility/exclusions, age, infection type/baseline symptoms, comorbidities and recruitment conditions are unverified. Review of the table remains pending with the user.
Reason for missing information: Exact eligibility/exclusions, age, infection type/baseline symptoms, comorbidities and recruitment conditions are unverified.
Required materials and conditions: Acute odontogenic infection population, eligibility/baseline severity and recruitment scope
Materials to obtain first: Population eligibility, baseline tables and centre-specific recruitment material
Further research: Proposed later material distinguishing the original population from other infections/vulnerable populations; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Acute odontogenic infection population, eligibility/baseline severity and recruitment scope must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Acute odontogenic infection population, eligibility/baseline severity and recruitment scope to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; Detailed population conditions are Chamgap design; M03 §3.2.1–3.2.4; Dose, duration and effect-modifier details are Chamgap design

Related sources S01

N10 · What denominators do 472 randomized and 235/237 represent?

Current findings: Original n is 472 randomized (235/237). Numbers and order are retained without calculating successful events, safety denominators or group dropout counts.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Explicit group labels for 235/237, actual assessed participants/successful events and analysis denominators are unverified. Review of the table remains pending with the user.
Reason for missing information: Explicit group labels for 235/237, actual assessed participants/successful events and analysis denominators are unverified.
Required materials and conditions: Distinguishing randomized counts/original group array from clinical-success analysis denominators
Materials to obtain first: Group-specific flowcharts and randomized/treated/assessed/analyzed denominator tables
Further research: Proposed report material linking separate denominators to clinical-success and safety results; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing randomized counts/original group array from clinical-success analysis denominators must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing randomized counts/original group array from clinical-success analysis denominators to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources S01

N11 · Are ITT, PP, missingness and noninferiority analyses distinguished?

Current findings: The stored summary provides a noninferiority conclusion and randomized counts. It does not establish concordant ITT/PP results or absence of missingness.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but ITT/PP definitions, exclusions/missingness, dropout, sensitivity and group analysis counts are unverified. Review of the table remains pending with the user.
Reason for missing information: ITT/PP definitions, exclusions/missingness, dropout, sensitivity and group analysis counts are unverified.
Required materials and conditions: Noninferiority analysis populations, missingness/discontinuation and sensitivity specifications
Materials to obtain first: SAP, ITT/PP outcome tables and missingness/follow-up flow material
Further research: Proposed later material disclosing analysis-population-specific noninferiority results and missingness assumptions; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Noninferiority analysis populations, missingness/discontinuation and sensitivity specifications must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Noninferiority analysis populations, missingness/discontinuation and sensitivity specifications to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01

N12 · What does observer blinding cover?

Current findings: The original is a randomized observer-blind phase 4 noninferiority trial. It is not changed into verified patient/administrator double blinding or allocation concealment.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Sequence generation/concealment, assessor/patient awareness, maintenance of blinding and breaches are unverified. Review of the table remains pending with the user.
Reason for missing information: Sequence generation/concealment, assessor/patient awareness, maintenance of blinding and breaches are unverified.
Required materials and conditions: Distinguishing observer blinding from patient/administrator/analyst blinding
Materials to obtain first: Randomization, blinding, adjudication procedures and actual-deviation material
Further research: Proposed report linking the scope of blinding to composite clinical-success adjudication; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing observer blinding from patient/administrator/analyst blinding must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing observer blinding from patient/administrator/analyst blinding to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

Related sources S01

N13 · How were VAS, fever and rescue antibiotics assessed?

Current findings: The existing verdict rationale describes a patient-centred endpoint combining pain/swelling VAS, fever and rescue antibiotics. Individual between-group benefits for components are not invented.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but VAS scale/baseline, fever definition, measurement timing, assessors and rescue-antibiotic criteria are unverified. Review of the table remains pending with the user.
Reason for missing information: VAS scale/baseline, fever definition, measurement timing, assessors and rescue-antibiotic criteria are unverified.
Required materials and conditions: Symptom measurement, assessors, composite adjudication and rescue treatment
Materials to obtain first: Symptom scales, rescue-treatment criteria and component outcome tables
Further research: Proposed outcome report separating symptoms from need for additional treatment; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Symptom measurement, assessors, composite adjudication and rescue treatment must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Symptom measurement, assessors, composite adjudication and rescue treatment to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3; Question-specific outcome adaptation is Chamgap design; M08 Table 8.2.a and M03 §3.2.4; Chamgap application; M03 §3.2.4; Chamgap interpretation boundary

Related sources S01

N14 · Are the 5~7-day end of treatment and later recurrence the same window?

Current findings: Original treatment/observation wording specifies 5~7 days and does not answer long-term recurrence or complications. It is not extended to long-term cure or recurrence prevention.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Exact visit windows, extension decisions, later recurrence/complication definitions and denominators are unverified. Review of the table remains pending with the user.
Reason for missing information: Exact visit windows, extension decisions, later recurrence/complication definitions and denominators are unverified.
Required materials and conditions: Acute end-of-treatment visits, duration variation and long-term follow-up
Materials to obtain first: Visit schedules, duration decisions and post-treatment follow-up results
Further research: Proposed material assessing acute success and later recurrence/complications separately; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Acute end-of-treatment visits, duration variation and long-term follow-up must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Acute end-of-treatment visits, duration variation and long-term follow-up to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

Related sources S01

N15 · How do drainage, dental procedures and concurrent exposure relate to results?

Current findings: The existing research explanation about difficulty giving placebo alone instead of drainage/antibiotics is historical design commentary. It is not changed into actual drainage or equivalent care for every participant.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Group differences in actual drainage/surgery, analgesics, concurrent care and treatment deviations/rescue are unverified. Review of the table remains pending with the user.
Reason for missing information: Group differences in actual drainage/surgery, analgesics, concurrent care and treatment deviations/rescue are unverified.
Required materials and conditions: Original ethical-control explanation and actual shared/group-specific procedures
Materials to obtain first: Shared/group-specific procedures, concomitant drugs, rescue and deviation material
Further research: Proposed report distinguishing contributions of the antibiotic comparison and concurrent procedures; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Original ethical-control explanation and actual shared/group-specific procedures must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Original ethical-control explanation and actual shared/group-specific procedures to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

Related sources S01

N16 · Can this comparison establish absolute efficacy versus placebo?

Current findings: The existing counterargument says absolute efficacy versus placebo was not tested. Active-control success rates are not used to calculate improvement without treatment, absolute effects or individual need.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Direct results for placebo/no-treatment comparisons are absent. Review of the table remains pending with the user.
Reason for missing information: Direct results for placebo/no-treatment comparisons are absent.
Required materials and conditions: Distinguishing active-control noninferiority from effects versus placebo/no treatment
Materials to obtain first: Current active-control results and original research material for separate comparisons
Further research: Proposed separate material for comparison questions distinguishing ethical/research conditions; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing active-control noninferiority from effects versus placebo/no treatment must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing active-control noninferiority from effects versus placebo/no treatment to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

Related sources S01

N17 · What are the prespecified clinical-success endpoint/timepoint and multiplicity?

Current findings: The original reports a prespecified noninferiority margin; this does not mean every symptom, visit or safety outcome was a prespecified primary endpoint.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Registration/protocol/SAP primary/secondary endpoints, visits, multiplicity and change histories remain unread. Review of the table remains pending with the user.
Reason for missing information: Registration/protocol/SAP primary/secondary endpoints, visits, multiplicity and change histories remain unread.
Required materials and conditions: Protocol-specified noninferiority specifications and hierarchy of other outcomes
Materials to obtain first: Original registration/protocol/SAP endpoint and analysis versions
Further research: Proposed material making prespecified plans and reported endpoints/timepoints comparable; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Protocol-specified noninferiority specifications and hierarchy of other outcomes must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Protocol-specified noninferiority specifications and hierarchy of other outcomes to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design; M08 Table 8.2.a and M04 §4.6.3; Chamgap application

Related sources S01

N18 · How are GSK funding, editorial support and employee authors distinguished?

Current findings: Original funding information specifies GSK funding and DiagnoSearch editorial support, with stock/equity disclosures by four GSK employee authors. This is not current external COI reading or independence certification.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Funding/editorial-support details, product supply, design/analysis/manuscript contributions and complete COI remain unread. Review of the table remains pending with the user.
Reason for missing information: Funding/editorial-support details, product supply, design/analysis/manuscript contributions and complete COI remain unread.
Required materials and conditions: Corporate funding, DiagnoSearch editorial support and employee stock/equity COI
Materials to obtain first: Original funding, product-supply, author-role, COI and contractual material
Further research: Proposed report disclosing support separately from research/manuscript control; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Corporate funding, DiagnoSearch editorial support and employee stock/equity COI must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Corporate funding, DiagnoSearch editorial support and employee stock/equity COI to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

Related sources S01

N19 · How are manufacturer-sponsored trials and independent replication recorded?

Current findings: Tancawan2015 AUG117044 and PMID26300919 link to the same stored report. Subclaim/parent, composite/component and safety results are not added as new independent trials or participant totals.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but New unique trial/participant or independent-replication counts are not established and remain null. Review of the table remains pending with the user.
Reason for missing information: New unique trial/participant or independent-replication counts are not established and remain null.
Required materials and conditions: One AUG117044 trial with shared bibliographic/subclaim/parent results
Materials to obtain first: Report relationships within the same trial and identifying material for independent studies
Further research: Proposed linking that distinguishes trial-family and outcome relationships when new material is provided; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for One AUG117044 trial with shared bibliographic/subclaim/parent results must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes One AUG117044 trial with shared bibliographic/subclaim/parent results to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources S01

N20 · Does NCT02141217 mean registration was read here?

Current findings: The original identifier NCT02141217 is retained exactly. Its presence is not upgraded to registration-content verification, confirmed prespecified endpoints/analyses or successful access here.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Original registration/changes, protocol and SAP remain unread, with no access attempted. Review of the table remains pending with the user.
Reason for missing information: Original registration/changes, protocol and SAP remain unread, with no access attempted.
Required materials and conditions: Distinguishing a literal registration number from actual reading of registration/changes/plans
Materials to obtain first: User-provided original registration/protocol/SAP copies
Further research: Proposed material providing report-plan links and change histories; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing a literal registration number from actual reading of registration/changes/plans must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing a literal registration number from actual reading of registration/changes/plans to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01

N21 · What safety outcomes do diarrhea, elevated liver enzymes and headache represent?

Current findings: The existing safety explanation reports diarrhea, elevated liver enzymes, headache and other events. Parent caution is an original value; no new event counts/rates, between-group harm differences or causal conclusions are created.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Group event counts/denominators, collection methods, severity, ascertainment/periods and CIs are unverified. Review of the table remains pending with the user.
Reason for missing information: Group event counts/denominators, collection methods, severity, ascertainment/periods and CIs are unverified.
Required materials and conditions: Originally reported adverse events and safety-event definitions/denominators
Materials to obtain first: Adverse-event tables, collection criteria and exposure/safety denominators
Further research: Proposed safety report distinguishing symptoms, laboratory abnormalities and discontinuation; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Originally reported adverse events and safety-event definitions/denominators must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Originally reported adverse events and safety-event definitions/denominators to connect material needed for the selected question with current material.
Application exceptions: This addresses harm-evidence gaps for the selected acute odontogenic infection clinical-success question. Original adverse-event/caution wording is not extended to overall safety or causal harm/rates, and no antibiotic-selection, dosing, administration/change or suitability guidance is created.
Referenced methods: M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Detailed distinctions are Chamgap design; M19 §19.1.2–19.2.4; Chamgap application; Chamgap interpretation boundary. M19 principles are referenced; no official causality tool was run

Related sources S01

N22 · What is known about allergy/liver risk, vulnerable populations and long-term outcomes?

Current findings: Original penicillin-allergy and liver-risk safety wording is preserved as historical text. It is not changed into drug-selection/change or suitability guidance, or long-term/vulnerable-population safety certification.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Risk-population inclusion/exclusion, occurrence/causality, long-term/delayed outcomes and missingness are unverified. Review of the table remains pending with the user.
Reason for missing information: Risk-population inclusion/exclusion, occurrence/causality, long-term/delayed outcomes and missingness are unverified.
Required materials and conditions: Original safety history and directly studied risk/follow-up scope
Materials to obtain first: Risk-population eligibility, exposure time, long-term/delayed and discontinuation safety material
Further research: Proposed safety material distinguishing the original population from vulnerable populations; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Original safety history and directly studied risk/follow-up scope must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Original safety history and directly studied risk/follow-up scope to connect material needed for the selected question with current material.
Application exceptions: This addresses harm-evidence gaps for the selected acute odontogenic infection clinical-success question. Original adverse-event/caution wording is not extended to overall safety or causal harm/rates, and no antibiotic-selection, dosing, administration/change or suitability guidance is created.
Referenced methods: M19 §19.1.2–19.2.4; internal application; M19 §19.2 design-specific harm questions; temporal-relationship details are internally designed; M19 §19.2.2–19.2.4 design considerations; detailed confounding records are internally designed; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application; M19 §19.1.2–19.2.4; internal application; Chamgap interpretation limits, informed by M19 principles without running an official causality tool

Related sources S01

N23 · Can adherence benefits be inferred from safety or convenience?

Current findings: The existing counterpoint says dosing convenience is not direct frequency-comparison evidence. Frequency is not used to calculate or recommend adherence rates, side-effect improvements or actual dosing behaviour.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Adherence, convenience scales and same-drug frequency-comparison results are unverified. Review of the table remains pending with the user.
Reason for missing information: Adherence, convenience scales and same-drug frequency-comparison results are unverified.
Required materials and conditions: BID convenience wording and direct adherence/harm/frequency comparisons
Materials to obtain first: Adherence/convenience tables and direct same-drug comparisons
Further research: Proposed material reporting clinical success, adherence and harms separately; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for BID convenience wording and direct adherence/harm/frequency comparisons must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes BID convenience wording and direct adherence/harm/frequency comparisons to connect material needed for the selected question with current material.
Application exceptions: This addresses harm-evidence gaps for the selected acute odontogenic infection clinical-success question. Original adverse-event/caution wording is not extended to overall safety or causal harm/rates, and no antibiotic-selection, dosing, administration/change or suitability guidance is created.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M19 §19.1.2–19.2.4; internal application

Related sources S01

N24 · What is the historical defect assessment for short follow-up, sample size and control?

Current findings: The existing research explanation says the under-200 criterion did not apply and that acute 5~7-day follow-up/active control were not counted as avoidable defects. This is not inherited as current reassessment, QA or certification of defect-free design.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but No original-text comparison or new defect/grade application is performed here. Review of the table remains pending with the user.
Reason for missing information: No original-text comparison or new defect/grade application is performed here.
Required materials and conditions: Original historical assessment of 472 people, 5~7 days and active control
Materials to obtain first: Original methods/verdict history or user-correction material
Further research: Proposed later record separating the original design assessment from new evidence-update events; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Original historical assessment of 472 people, 5~7 days and active control must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Original historical assessment of 472 people, 5~7 days and active control to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

Related sources S01

N25 · Can Korean prescribing/practicality wording be used as current recommendations?

Current findings: Original Korean dental-prescribing/practicality wording is retained in the complete existing review summary. No current policy, approval, product-selection, frequency or treatment recommendations are added.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but Current operational/recommendation updates or direct evidence for other formulations/populations/durations are outside this scope. Review of the table remains pending with the user.
Reason for missing information: Current operational/recommendation updates or direct evidence for other formulations/populations/durations are outside this scope.
Required materials and conditions: Distinguishing original advertising-interpretation history from current policy/product/dosing verification
Materials to obtain first: Separate policy/direct-research material provided if the scope expands
Further research: Proposed later material record distinguishing historical wording from current material; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Distinguishing original advertising-interpretation history from current policy/product/dosing verification must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Distinguishing original advertising-interpretation history from current policy/product/dosing verification to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M03 §3.2.1; detailed population conditions are internally designed; M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01

N26 · At what level were the stored summary, external papers and source links read?

Current findings: The complete stored summary was read for production and marked as summary reading. Only the original PubMed URL is retained; paper/abstract/full text, registration, plans and COI remain unread.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but External access, link/click tests and original-source identity/content comparisons were not performed. Review of the table remains pending with the user.
Reason for missing information: External access, link/click tests and original-source identity/content comparisons were not performed.
Required materials and conditions: Complete original stored summary; PMID26300919, registration/plans/COI remain unread
Materials to obtain first: User-provided paper, registration, plan and COI copies
Further research: Proposed later record separating actual acquisition/reading scope for each material; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Complete original stored summary; PMID26300919, registration/plans/COI remain unread must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Complete original stored summary; PMID26300919, registration/plans/COI remain unread to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01

N27 · How are Korean/English, dates, corrections, empty values and cross-check history retained?

Current findings: Complete Korean/English articles, subclaim grade C, parent C50/caution, unrecorded precision/false flags, empty correction/deliberation values and reference date are preserved in their original form. Original cross-check wording is historical and does not mean completed review here.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but No translation/content review, correction, new verdict or external update is performed here. Review of the table remains pending with the user.
Reason for missing information: No translation/content review, correction, new verdict or external update is performed here.
Required materials and conditions: Subclaim C/note, parent C50/caution, 2026-08-26 and original false/null/empty values
Materials to obtain first: Complete original copies, verdict history or user-corrected material
Further research: Proposed later production record separating original preservation from correction/update events; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Subclaim C/note, parent C50/caution, 2026-08-26 and original false/null/empty values must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Subclaim C/note, parent C50/caution, 2026-08-26 and original false/null/empty values to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01

N28 · Are condition freezing/application, case storage and user review separate events?

Current findings: Condition preservation/application, case production and completed review are separate records. Review of the existing content is incomplete and is distinguished from production.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a draft presentation of the stored summary. Some information exists, but User review is incomplete; no post-storage rereading, review, checks/tests or link/screen verification is performed. Review of the table remains pending with the user.
Reason for missing information: User review is incomplete; no post-storage rereading, review, checks/tests or link/screen verification is performed.
Required materials and conditions: Prior condition storage, freezing, separate application/case and incomplete-review flags
Materials to obtain first: Separate event records when user comments or additional original material are provided
Further research: Proposed later work recording production separately from user correction/review events; no new investigation, calculation or trial is performed here.
Remaining uncertainty: This presentation links stored wording. It does not constitute external full-text comparison, an efficacy judgment or completed QA.
Conditions for verification: Relevant original material and analysis scope for Prior condition storage, freezing, separate application/case and incomplete-review flags must be provided, with unverified matters distinguished. Stored wording is linked here; user review remains pending.
Why this condition is needed: This production item distinguishes Prior condition storage, freezing, separate application/case and incomplete-review flags to connect material needed for the selected question with current material.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01